Intravenous Immunoglobulin Market - Forecast(2024 - 2030)

Intravenous Immunoglobulin Market Overview                                      

Intravenous Immunoglobulin Market size is estimated to reach $17.1 billion by 2026, growing at a CAGR of 7.5% during the forecast period 2021-2026. Intravenous Immunoglobulins are antibodies that are part of the blood's plasma and are produced naturally by the body's immune system. Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with various immunodeficiency diseases and bleeding disorders. These are glycoproteins made by the immune system of healthy people for fighting infections. It works in different ways to decrease inflammation in the body. Rise in the adoption of glycoproteins for the treatment of various immunodeficiency diseases, growing demand for immunoglobulin G (IgG) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia, and increasing awareness about the efficiency of intravenous immunoglobulins as a treatment option are the factors that are set to drive the growth of the Intravenous Immunoglobulin Market for the period 2021-2026.

Intravenous Immunoglobulin Market Report Coverage

The report: “Intravenous Immunoglobulin Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Intravenous Immunoglobulin Market.

By Product Type: Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), and Immunoglobulin D (IgD).
By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Inflammatory Myopathies, Guillain-Barre Syndrome, Specific Antibody Deficiency, and Others.
By Geography: North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia & New Zealand, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World (Middle East and Africa).

Key Takeaways

Intravenous Immunoglobulin Market Segment Analysis-By Product Type

The Intravenous Immunoglobulin Market based on the Product Type can be further segmented into Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), and Immunoglobulin D (IgD). The Immunoglobulin G (IgG) segment held the largest share in 2020 owing to its ability to control infection of body tissues and to protect the body from infection by binding many kinds of pathogens, such as viruses and fungi. 

The rise in the applications of Immunoglobulin G (IgG) for the treatment of hypogammaglobulinemia is driving the growth of the Intravenous Immunoglobulin Market. The Immunoglobulin A (IgA) segment is estimated to be the fastest growing segment with a CAGR of 8.3% over the period 2021-2026. This growth is owing to its ability to inhibit bacterial adhesion to epithelial cells and neutralize both bacterial and virus toxins. Immunoglobulin A (IgA) also acts as the first line of defense in the resistance against infection.

Intravenous Immunoglobulin Market Segment Analysis-By Application

The Intravenous Immunoglobulin Market based on the Application can be further segmented into Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Inflammatory Myopathies, Guillain-Barre Syndrome, Specific Antibody Deficiency, and Others. The Hypogammaglobulinemia segment held the largest share in 2020 and is also estimated to be the fastest growing segment with a CAGR of 8.4% over the period 2021-2026. This growth is owing to the factors such as the growing prevalence of hypogammaglobulinemia across the world and the rise in the research and development activities by the key players to developed advanced therapies for the treatment of hypogammaglobulinemia. 

The rise in the adoption of intravenous immunoglobulins for the treatment of hypogammaglobulinemia is driving the growth of the Intravenous Immunoglobulin Market. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) segment held the second largest share in 2020 owing to the factors such as increase in the prevalence of diabetes mellitus and growing awareness among the consumers about the benefits of minimally invasive and user-friendly procedures for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

Intravenous Immunoglobulin Market Segment Analysis-By Geography

North America held the largest share with 29% of the overall market in 2020. The growth in this segment can be attributed to the factors such as increase in the demand for immunoglobulin G (IgG) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and rise in the research and development activities by the key players to developed advanced therapies for the treatment of hypogammaglobulinemia. 

The rise in the adoption of glycoproteins for the treatment of various immunodeficiency diseases is driving the growth of the Intravenous Immunoglobulin Market. Asia-Pacific segment is estimated to be the fastest growing segment over the period 2021-2026. The growth in this segment is owing to the factors such as growing awareness about the efficiency of intravenous immunoglobulins as a treatment option and the rise in the adoption of advanced technologies pertaining to immunoglobulin production.

Intravenous Immunoglobulin Market Drivers

Rise in the Adoption of Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Intravenous Immunoglobulins are increasingly being used for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) owing to its associated benefits such as minimally invasive and user-friendly treatment options. These glycoproteins act as a critical part of the immune response by specifically binding to particular antigens, which is one of the major factors driving the growth of the Intravenous Immunoglobulin Market.

Increase in the Prevalence of Immunodeficiency Diseases and Bleeding Disorders

With an increase in the prevalence of immunodeficiency diseases and bleeding disorders across the world, there is an increase in the awareness among consumers about the efficiency of intravenous immunoglobulins as a treatment option. The key players are also focusing on developed advanced intravenous immunoglobulins for the treatment of various immunodeficiency diseases, which is further propelling the growth of the Intravenous Immunoglobulin Market.

Intravenous Immunoglobulin Market Challenges  

High Cost of Intravenous Immunoglobulin Therapy

The government of several nations and other organizations are increasing their initiatives to enhance awareness among people about immunodeficiency diseases and the efficiency of various intravenous immunoglobulins as a treatment option. However, the high cost of Intravenous Immunoglobulin therapy is one of the major factors that is estimated to reduce the growth of the Intravenous Immunoglobulin Market.

Intravenous Immunoglobulin Market Competitive Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Intravenous Immunoglobulin Market. Key companies of this market include Baxter International Inc, Takeda Pharmaceuticals, Bayer Healthcare, AscellaHealth, Kedrion Biopharma, Grifols, Biotest AG, Octapharma AG, LFB group, and Kedrion Biopharma Inc among others.

Partnerships/Product Launches

• In November 2020, AscellaHealth has launched its Intravenous Immunoglobulin (IVIG) Medication Therapy to support the aim of the Immune Deficiency Foundation (IDF) and to enhance patient care and cost management approaches.
• In June 2020, Grifols has launched its hyperimmune immunoglobulin for the treatment of infections that are applied to healthcare emergencies like the Ebola outbreak and to prevent infections in cases of accidental exposure to infectious agents associated with autoimmune diseases.
• In April 2020, Kedrion Biopharma has entered into a partnership with Kamada for the Development, and Distribution of Intravenous Immunoglobulin to make a significant impact for patients in need during the pandemic.

Relevant Reports:

Monoclonal Antibodies Market - Forecast (2021 - 2026)

Report Code: HCR 0320

Injectable Drug Delivery Market - Forecast (2021 - 2026)

Report Code: HCR 0023

For more Lifesciences and Healthcare Market reports, please click here